Table 2. Comparison of LABA prescribing in 7 European databases stratified by indication for the year 2008.
| THIN | CPRD | Mondriaan–AHC | Mondriaan–NPCRD | BIFAP | Bavarian DB | DKMA | ||
|---|---|---|---|---|---|---|---|---|
| Persons with at least one LABA prescription | Total | 128,220 | 154,505 | 5,159 | 8,964 | 56,144 | 302,993 | 153,630 |
| Asthma | 79,540 (62.0%) | 96,687 (62.6%) | 2,706 (52.5%) | 3,529 (39.4%) | 25,582 (45.6%) | 109,639 (36.2%) | n.a. | |
| COPD | 13,776 (10.7%) | 15,703 (10.2%) | 962 (18.6%) | 2,049 (22.9%) | 12,704 (22.6%) | 56,489 (18.6%) | n.a. | |
| Asthma and COPD | 30,389 (23.7%) | 36,152 (23.4%) | 164 (3.2%) | 1,447 (16.1%) | 2,369 (4.2%) | 103,365 (34.1%) | n.a. | |
| Other or unknown | 4,515 (3.5%) | 5,963 (3.9%) | 1,327 (25.7%) | 1,939 (21.6%) | 15,489 (27.6%) | 33,500 (11.1%) | n.a. | |
| Total number of persons in the database at mid-year | Total | 3,704,927 | 4,273,098 | 141,419 | 323,175 | 1,441,009 | 10,415,393 | 5,242,117 |
| Asthma | 497,585 (13.4%) | 586,707 (13.7%) | 12,619 (8.9%) | 16,428 (5.1%) | 112,562 (7.8%) | 569,482 (5.5%) | n.a. | |
| COPD | 40,233 (1.1%) | 41,248 (1.0%) | 2,075 (1.5%) | 4,532 (1.4%) | 27,338 (1.9%) | 409,825 (3.9%) | n.a. | |
| Asthma and COPD | 45,664 (1.2%) | 51,224 (1.2%) | 253 (0.2%) | 2,496 (0.8%) | 3,266 (0.2%) | 246,500 (2.4%) | n.a. | |
| Crude annual PPR per 100 persons (95% CI) | Total | 3.5 (2.9–4.1) | 3.6 (3.1–4.2) | 3.6 (1.4–8.4) | 2.8 (1.4–5.3) | 3.9 (3.0–5.0) | 2.9 (2.0–4.1) | 2.9 (2.5–3.4) |
| Asthma | 16.0 (13.0–19.5) | 16.5 (13.7–19.7) | 21.4 (6.4–49.8) | 21.5 (7.6–46.2) | 22.7 (15.9–31.3) | 19.3 (16.2–22.7) | n.a. | |
| COPD | 34.2 (21.5–49.8) | 38.1 (24.8–53.3) | 46.4 (8.5–89.0) | 45.2 (13.6–81.2) | 46.5 (29.4–64.4) | 13.8 (10.8–17.5) | n.a. | |
| Asthma and COPD | 66.5 (52.0–78.5) | 70.6 (56.9–81.3) | 64.4 (58.4–70.1) | 58.0 (14.3–92.0) | 72.5 (24.4–96.3) | 41.9 (35.9–48.2) | n.a. | |
| Standardised annual PPR per 100 persons (95% CI) | Total | 3.5 (3.5–3.5) | 3.6 (3.5–3.6) | 4.4 (4.3–4.6) | 2.9 (2.8–3.0) | 4.0 (3.9–4.0) | 2.8 (2.8–2.8) | 3.0 (2.9–3.0) |
| Asthma | 18.1 (18.0–18.2) | 18.3 (18.2–18.4) | 25.5 (24.5–26.4) | 24.7 (23.9–25.4) | 28.7 (28.4–29.0) | 19.8 (19.6–19.9) | n.a. | |
| COPD | 17.5 (16.5–18.5) | 18.6 (17.8–19.5) | 28.0 (23.1–32.9) | 30.3 (25.0–35.5) | 19.7 (19.0–20.5) | 9.4 (9.3–9.5) | n.a. | |
| Asthma and COPD | 46.8 (45.6–48.0) | 50.6 (49.2–52.0) | 40.8 (35.9–45.7) | 46.7 (42.3–51.0) | 42.8 (40.1–45.5) | 37.9 (37.7–38.2) | n.a. |
LABA: Long-acting beta-2-agonist.
n.a.: not available.
PPR: Period prevalence rate.
CI: Confidence interval.